Emerging treatments in diabetic wound care

Wounds

Volumn 14, Issue 1, 2002, Pages 2-10

  Dinh, Thanh ^a   Pham, Hau ^a   Veves, Aristidis ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044532675     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Borssen B, Bergenheim T, Lithner F. The epidemiology of foot lesions in diabetic patients aged 15-50 years. Diabetic Med 1990;7:438-44.
2. Kumar S, Ashe HA, Fernando DJS, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: A population-based study. Diabetic Med 1994;11:480-4.
3. Palumbo PJ, Melton LJ III. Peripheral vascular disease and diabetes. Diabetes in America. NIH Publ. No. 85-1468. Washington, DC: US Government Printing Office, 1985.
4. Loots MA, Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998;111:850-7.
5. Jude EB, Boulton AJ, Ferguson MW, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: Possible modulatory effects by transforming growth factor beta 1. Diabetologia 1999;42:748-57.
6. Loots MA, Lamme EN, Mekkes JR, et al. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 1999;291:93-9.
7. Schilling JA. Wound healing. Physiol Rev 1968;48:374-423.
8. Zykova SN, Jenssen TG, Berdal M, et al. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000;40:1451-8.
9. Spravchikov N, Sizyakov G, Gartsbein M, et al. Glucose effects on skin keratinocytes. Diabetes 2001;50:1627-35.
10. Cooper DM, Yu EZ, Hennesey P, et al. Determination of endogenous cytokines in chronic wounds. Ann Surg 1994;219:688-92.
11. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21(5)822-7.
12. Broadley K, Aquino A, Woodward S, et al. Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest 1989;61:571-5.
13. Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care 1995;18(1):64-9.
14. Robson MC, Phillips LG, Lawrence T, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992;216:401-8.
15. Detmar M, Brown LF, Berse B, et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor in human skin. J Invest Dermatol 1997;108:263-8.
16. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes: Implication for normal and impaired wound healing. J Biol Chem 1995;270:12607-13.
17. Schaffer MR, Tantry U, Efron PA, et al. Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation. Surgery 1997;121(5):513-9.
18. Shi HP, Efron DT, Most D, Barbul A. The role of iNOS in wound healing. Surgery 2001;130(2):225-9.
19. Field FK, Kerstein MD. Overview of wound healing in a moist environment. Am J Surg 1994;167(1A):2S-6S.
20. Hansson C. Interactive wound dressings: A practical guide to their use in older patients. Drugs & Aging 1997;11:271-84.
21. Wijetunge DB. Management of acute and traumatic wounds: Main aspects of care in adults and children. Am J Surg 1194;167(1A)suppl:56s-60s.
22. Lawrence C. Dressings and wound infection. Am J Surg 1994;167(1A)suppl: 21s-24s.
23. Thomas S. Hydrocolloids update. J Wound Care 1992;1:27-30.
24. Ono I, Gunji H, Zhang JZ, et al. Studies on cytokines related to wound healing in donor site wound fluid. J Dermatol Sci 1995;10:241-5.
25. Jones V. Alginate dressings and diabetic foot lesions. Diab Foot 1999;2:8-14.
26. Thomas S, Hay NP. Assessing the hydroaffinity of hydrogel dressings. J Wound Care 1995;3:89-91.
27. Geronemus RG, Mertz PM, Eaglstein WH. Wound healing: The effects of topical agents. Arch Dermatol 1979;115:1311-3.
28. Kashyap A, Beezhold D, Wiseman J, et al. Effect of povidone-iodine ointment on wound healing. Am J Surg 1995;61:486-91.
29. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-46.
30. Witte MB. General principles of wound healing. Surg Clin North Am 1997;77:509-28.
31. Muhart M, McFalls S, Kirsner RS, et al. Behavior of tissue-engineered skin. Arch Dermatol 1999135:913-8.
32. Teepe RGC, Koebrugge ED, Ponec M, Vermeer BJ. Fresh versus cryopreserved allografts for the treatment of chronic skin ulcers. Br J Dermatol 1990;122:81-9.
33. Teepe RGC, Roseeuw DI, Hermans D, et al. Randomized trial comparing cryopreserved cultured epidermal allografts with hydrocolloid dressings in healing chronic venous ulcers. J Am Acad Dermatol 1993;29:982-8.
34. Phillips TJ. Cultured skin grafts: Past, present, future. Arch Dermatol 1988;124:1035-8.
35. Phillips TJ, Gilchrest BA. Clinical applications of cultured epithelium. Epith Cell Biol 1992;1:39-46.
36. Phillips T, Bhawan J, Leigh IM, et al. Cultured ' epidermal allografts: A study of differentiation and allograft survival. J Am Acad Dermatol 1990;23:189-98.
37. Phillips T. Cultured epidermal allografts: A temporary or permanent solution? Transplantation 1991;51:937-41.
38. Clark RAF. Basics of cutaneous wound repair. J Dermatol Surg Oncol 1993;19:693-706.
39. Krant D, Eckhardt M, Patton ML, et al. Combined simultaneous application of cultured epithelial autograft and Alloderm. WOUNDS 1995;7:137-42.
40. Kolenik SA III, Leffell DJ. The use of cryopreserved human skin allografts in wound healing following Mohs surgery. Dermatol Surg 1995;21:615-20.
41. Hansbrough JF, Dore C, Hansbrough WB. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J Burn Care Rehabil 1992;13:519-29.
42. Hansbrough JF, Cooper ML, Greenleaf G, et al. Evaluation of a biodegradable matrix containing cultured human fibroblasts as a dermal replacement beneath meshed split-thickness skin grafts. Surgery 1992;11:438-46.
43. Cooper ML, Hansbrough JF, Spielvogel RL, et al. In-vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991;12:243-48.
44. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19(4):350-4.
45. Eaglstein WH, Iriondo M, Laszio K. A composite skin substitute (Graftskin) for surgical wounds: A clinical experience. Dermal Snrg 1995;21:834-9.
46. Brem H, Balledux J, Bloom T, Kerstein M, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. Arch Surg 2000;135:627-34.
47. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care 2001;24(2):290-5.